

Ocrevus Standing Order Form

Patient Information

Patient Name: _____ Date: _____

Physician: _____ Primary Diagnosis: _____

Allergies: _____ DOB: _____ Ht: _____ in/cm Wt: _____ lb/kg

Initiate the following orders: ARJ policy and protocol to be provided upon request.

Medication	Maintenance Dosing	Directions	Quantity/Refills
Ocrevus: <input checked="" type="checkbox"/> 300 mg/250 mL NS IV day 1 and day 15 <input type="checkbox"/> Initial dose completed. Dispense maintenance dose only.	<input checked="" type="checkbox"/> 600 mg/ 500 mL NS IV every 24 weeks.	<input checked="" type="checkbox"/> Infuse per manufacturer guidelines	Dispense: 1 month supply on all selected medications Refill x12 months unless otherwise noted <input type="checkbox"/> Other: _____
<input checked="" type="checkbox"/> RN to start peripheral IV or use existing CVC. RN to administer catheter flushing per ARJ Policy and Procedure <input checked="" type="checkbox"/> Give standard premedication 30 mins prior to infusion Antihistamine: Diphenhydramine 25-50 mg po Steroid: Methylprednisolone 100mg slow IV push over 5 mins Pain/Fever: Acetaminophen 325-650mg po Alternative premedications (if checked, item will replace the indicated standard above premedication) Antihistamine: <input type="checkbox"/> Diphenhydramine 50mg IV diluted in D5W or NS 50-100ml, infused over 10-15 mins. <input type="checkbox"/> Fexofenadine 180mg po <input type="checkbox"/> Cetirizine 10mg po Steroid: <input type="checkbox"/> Methylprednisolone _____ mg slow IV push over 5 mins. Pain/Fever: <input type="checkbox"/> Acetaminophen _____ mg po <input checked="" type="checkbox"/> RN to monitor vital signs at start of infusion, every 30 minutes and 1 hour post infusion. RN to educate patient on possible side effects, allergic reactions, and when to contact physician. <input checked="" type="checkbox"/> RN to instruct patient to hydrate pre/post infusion. RN to instruct patient to take Diphenhydramine 25-50 mg po and Acetaminophen 325-650 mg po every 4-6 hours for 24-48 hours as needed to prevent/treat post infusion headache. <input type="checkbox"/> Other: _____			

Adverse Reaction Orders: (Dispense 1 dose of each medication below)

In the event of an infusion reaction the following orders will be followed and physician will be notified.

For mild reactions such as: itching, flushing, rash – reduce the infusion rate to half the rate at the onset of reaction and maintain reduced rate for at least 30min. If symptoms resolve rate can be increased per manufacturer guidelines. Administer appropriate medication based on symptoms occurring.

For severe reactions such as: bronchospasm, dyspnea – stop infusion and administer appropriate medication based on symptoms occurring. Restart the infusion only after all symptoms have resolved. When restarting, begin at half of the infusion rate at the time of onset of reaction. If this rate is tolerated increase the rate per manufacturer guidelines.

- STOP infusion.** Infuse D5W or NS at 20 mL/hr to keep line open, may increase to 100-250 mL/hr for hydration.
- Diphenhydramine:** 50 mg IV diluted in D5W or NS 50-100 mL, infused over 10-15 minutes or 50 mg/10 mL NS IV push over 2-3 minutes, as tolerated.
- Methylprednisolone:** 125 mg (OR _____ mg) slow IV push over 5 minutes.
- Acetaminophen:** 325-650 mg (OR _____ mg) po at onset of symptoms.
- Ondansetron:** 4 mg slow IV push over 5 minutes or 4 mg ODT.
- Epinephrine:** (1:1000) by weight for use IM or SQ in anaphylactic reaction. May repeat one time. EMS/911 will be called if used.

By signing I certify that the use of the indicated treatment is medically necessary and I will be supervising the patient's treatment.

ARJ Infusion Services has my permission to contact the patient's health plan to obtain any authorizations necessary to enable it to receive payment for services.

 Physician Signature Required - Substitution Permitted

 Physician Signature Required - Dispense as Written

Date: _____ | Date: _____

Confidential Health Information: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization and under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure and confidential manner. Re-disclosure of this information is prohibited by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state law. Important Warning: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any discrimination, distribution, or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately.